Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
This study has been terminated.
( Financing and re-organization )
Study NCT00386516   Information provided by Galectin Therapeutics Inc.

First Received on October 10, 2006.   Last Updated on March 13, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer of the Bile Duct
Gallbladder Cancer
Additional conditions recognized in this trial
Bile Duct Neoplasms
Gallbladder Neoplasms
More general conditions related to this trial
Bile Duct Diseases
Biliary Tract Diseases
Biliary Tract Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gallbladder Diseases
Neoplasms
Neoplasms by Site
Interventions listed in this trial
GM-CT-01
5-Fluorouracil
Additional drug interventions recognized in this trial
Fluorouracil
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Galectin Therapeutics Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services